Teva Agrees To Suspend Sales Of Moexipril Pending Patent Suit Outcome

Law360, New York (September 13, 2004, 12:00 AM EDT) -- Israeli generics maker Teva Pharmaceutical Industries Ltd. has agreed to stop selling its generic version of Schwarz Pharma AG's Univasc hypertension drug until the resolution of a patent infringement lawsuit in New Jersey district court.

Teva said the suspension was part of an agreement reached with Schwarz. Under the agreement, Teva will suspend all manufacturing and sales of its Moexipril HCl tablets until the outstanding litigation at the New Jersey District Court is cleared up.

Teva began selling Moexipril tablets in two doses, 7.5 mg and...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.